Currently, there are 406.39M common shares owned by the public and among those 302.82M shares have been available to trade.
The company’s stock has a 5-day price change of 2.34% and -35.26% over the past three months. AGL shares are trading -68.69% year to date (YTD), with the 12-month market performance down to -78.70% lower. It has a 12-month low price of $3.07 and touched a high of $20.37 over the same period. AGL has an average intraday trading volume of 4.77 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.48%, -19.63%, and -37.45% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Agilon Health Inc (NYSE: AGL) shares accounts for 86.90% of the company’s 406.39M shares outstanding.
It has a market capitalization of $1.62B and a beta (3y monthly) value of 0.54. The earnings-per-share (ttm) stands at -$0.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.50% over the week and 9.52% over the month.
Earnings per share for the fiscal year are expected to increase by 25.75%, and 59.67% over the next financial year.
Looking at the support for the AGL, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on May 30, 2024, with the firm’s price target at $6. Citigroup coverage for the Agilon Health Inc (AGL) stock in a research note released on April 22, 2024 offered a Neutral rating with a price target of $6. Barclays was of a view on March 06, 2024 that the stock is Underweight, while TD Cowen gave the stock Market Perform rating on February 26, 2024, issuing a price target of $12- $6.50. Jefferies on their part issued Hold rating on February 26, 2024.
